There are currently 89 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Asthma participants are California, Texas, Florida and Ontario.
SMART@Home Feasibility Trial
NCT06159127
Recruiting
The proposed research addresses the limitations or lack of a digital platform to provide remote care of medically complex patients. Previous attempts have had poor clinical validity and suffered lack of patient engagement. The study team will deconstruct the previously implemented SMART platforms to create a roadmap, platform, and template to guide clinicians to create new tools. Results from Phase 1 of this project highlighted the need for connectivity between the SMART@Home app and Bluetooth-... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
02/10/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Asthma, Asthma in Children
Register for Updates
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315
Recruiting
This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A,... Read More
Gender:
ALL
Ages:
Between 2 years and 5 years
Trial Updated:
05/22/2025
Locations: Phoenix Children's Hospital- Site Number : 8400001, Phoenix, Arizona +72 locations
Conditions: Wheezing, Asthma
Register for Updates
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
Recruiting
The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/21/2025
Locations: Teva Investigational Site 12087, Phoenix, Arizona +49 locations
Conditions: Asthma
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to assess the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each particip... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
05/21/2025
Locations: Teva Investigational Site 15768, Dothan, Alabama +369 locations
Conditions: Asthma
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/20/2025
Locations: Chandler Clinical Research Trials- Site Number : 8400075, Chandler, Arizona +159 locations
Conditions: Asthma
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
05/20/2025
Locations: Research Site, Mobile, Alabama +84 locations
Conditions: Asthma
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/19/2025
Locations: Research Site, Birmingham, Alabama +52 locations
Conditions: Asthma
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/19/2025
Locations: Research Site, Mesa, Arizona +230 locations
Conditions: Asthma
Register for Updates
NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)
NCT02327897
Recruiting
Background: - Asthma is a serious clinical and public health problem. Researchers want to collect data to better understand how bacteria and other things in the environment can affect people's asthma. Eligibility: - Nonsmoking adults age 18 - 60 who have moderate to severe asthma. Design: * Participants will complete a medical history form before the first visit. * Study visits will include collecting medical history, and conducting physical exam, lung and smoking tests. Participants will g... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/17/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Asthma
Register for Updates
Personalized Environment and Genes Study
NCT00341237
Recruiting
Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cannot change their genetic composition, we do have the ability both personally and as a society, to influe... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/17/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Diabetes, Heart Disease, Asthma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/16/2025
Locations: Orso Health, La Jolla, California +10 locations
Conditions: Asthma
Register for Updates
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/14/2025
Locations: Velocity Clinical Research, Mobile, Mobile, Alabama +6 locations
Conditions: Asthma
Register for Updates